The TUSC2 (Tumor Suppressor Candidate 2) gene, located on chromosome 3p21.3. encodes a protein implicated in tumor suppression across multiple cancers. Initially identified as a candidate tumor suppressor due to frequent deletions or epigenetic silencing in lung, ovarian, and breast cancers, TUSC2 regulates key cellular processes, including apoptosis, cell cycle arrest, and inhibition of oncogenic signaling pathways such as PI3K/AKT and EGFR. Its role in modulating mitochondrial function and reactive oxygen species (ROS) further links it to chemosensitivity and radiation response. TUSC2 antibodies are essential tools for detecting protein expression levels in research and diagnostics, aiding studies on its mechanistic contributions to cancer progression and therapeutic resistance. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess TUSC2 downregulation in tumors, correlate expression with clinical outcomes, and evaluate its potential as a biomarker or therapeutic target. Commercial TUSC2 antibodies are typically developed in rabbit or mouse hosts, targeting specific epitopes with validated specificity. Ongoing research explores TUSC2's utility in gene therapy and combination therapies, emphasizing the antibody's critical role in advancing translational oncology.